ALEC vs ALLO

Alector, Inc. vs Allogene Therapeutics, Inc. — Valuation Comparison 2026

ALEC

Biotechnology
Alector, Inc.
Quality
5.7
out of 10
Value Trap
32
LOW
Price
$2.15
Last close
Models
9/13
Active
VS

ALLO

Biotechnology
Allogene Therapeutics, Inc.
Quality
4.7
out of 10
Value Trap
45
WARN
Price
$2.25
Last close
Models
9/13
Active

Model-by-Model Comparison

ModelType ALEC Fair ValueALEC Upside ALLO Fair ValueALLO Upside
Bayesian DCF Intrinsic $0.66 -69.4% $0.56 -75.3%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $0.93 -56.6% $0.05 -97.9%
Dynamic NAV Asset-Based $•••.•• ••.•% $•••.•• ••.•%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for ALEC vs ALLO — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

ALEC vs ALLO — Which Stock Is More Undervalued?

ALEC scores higher with a 5.7/10 quality rating vs ALLO's 4.7/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Alector, Inc. (ALEC) and Allogene Therapeutics, Inc. (ALLO) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

ALEC currently trades at $2.15 with a QOC of 5.7/10, while ALLO trades at $2.25 with a QOC of 4.7/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).